FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Metformin enhances the pathological response in nondiabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: A randomized controlled trial. PMID 42456199 · J Pharmacol Exp Ther · 2026-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial. PMID 42330568 · Eur J Cancer · 2026-Jun-19 The record describes a school-based smoking prevention trial, not a human malignant-neoplasm trial. It does not involve a drug-containing intervention or a time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial. PMID 42319531 · Qual Life Res · 2026-Jun-19 The record is an original secondary analysis of a randomized trial, focusing on the prognostic association between patient-reported outcomes and overall survival. It is not the primary or key secondary report of the trial's efficacy results. The phase of the trial is not explicitly stated in the provided metadata, requiring manual review for phase confirmation. The report does not meet the strict criterion of being the primary formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial comparing the effect of salivary substitute and fluoride varnish on radiation caries in irradiated head and neck cancer patients. PMID 42319482 · Support Care Cancer · 2026-Jun-19 The study is a randomized trial in human head and neck cancer patients, but it evaluates preventive dental interventions (salivary substitute, fluoride varnish) for radiation caries, not a drug-containing intervention for cancer treatment. The primary endpoint is DMFS score, a measure of dental decay, not a time-to-event efficacy endpoint. No Phase III/IIIb or Phase II/III designation is provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence. PMID 42352517 · Cancers (Basel) · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15-35 Years. PMID 42347661 · Vaccines (Basel) · 2026-Jun-18 The study is a Phase III randomized trial of an HPV vaccine (drug intervention) in humans with an oncology context (cancer prevention), but the primary endpoint is immunogenicity (GMT), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or analysis involving Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. PMID 42315278 · BMJ Open · 2026-Jun-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial. PMID 42313403 · JAMA Otolaryngol Head Neck Surg · 2026-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study. PMID 42107346 · Eur J Cancer · 2026-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study. PMID 42310529 · J Headache Pain · 2026-Jun-17 The study is an open-label extension of a Phase 3 randomized trial, but it evaluates erenumab for chronic migraine, which is not an oncology indication. Therefore, it fails the core oncology criterion. Furthermore, the primary outcomes reported are safety and clinical global impression scores, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial. PMID 42310313 · Nat Commun · 2026-Jun-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. PMID 42309209 · Ann Oncol · 2026-Jun-17 The record is a human oncology, randomized trial with drug intervention and time-to-event efficacy endpoints (PFS, OS) reported as original results. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, keywords, publication type). The deterministic review flagged phase evidence as unclear. Therefore, the required criterion 'phase3_or_definitive' cannot be explicitly confirmed, making the study ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of PET-guided BrECADD with chemotherapy in advanced-stage, classical Hodgkin lymphoma. PMID 42304371 · Cost Eff Resour Alloc · 2026-Jun-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial. PMID 42303632 · Signal Transduct Target Ther · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series. PMID 42303407 · BMJ Open · 2026-Jun-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Early Economic and Patient-Centered Outcomes Before Spine Metastases Radiation Therapy From an Ongoing Phase II Randomized Controlled Trial. PMID 42302152 · Am J Clin Oncol · 2026-Jun-16 This is an original report of an ongoing randomized phase II/III oncology trial (SPORTSMEN) comparing two radiotherapy regimens (SBRT vs. EBRT) for spinal metastases. However, it is a secondary analysis focusing on early economic and patient-reported outcomes (financial toxicity, quality of life), not a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The intervention is non-drug (radiotherapy only), so it fails the drug-intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Inpatient Metastatic Spine Score: Prospective Validation on an Ongoing Multicenter Phase II Randomized Controlled Trial. PMID 42302111 · Am J Clin Oncol · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. PMID 42299497 · Br J Haematol · 2026-Jun-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Financial Toxicity of Shorter Versus Longer Partial Breast Irradiation: A Randomized Clinical Trial. PMID 42297155 · Int J Radiat Oncol Biol Phys · 2026-Jun-15 The study is a randomized Phase 3 oncology trial in humans with original results, but it evaluates radiation dosing schedules (a non-drug intervention) and its primary endpoint is financial toxicity (a patient-reported outcome), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials. PMID 42240563 · Cancer · 2026-Jun-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial. PMID 41849224 · Clin Cancer Res · 2026-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial. PMID 41587113 · Clin Cancer Res · 2026-Jun-15 The study is a Phase IIIb trial with a drug intervention and PFS endpoint, but the report is a secondary biomarker analysis of the trial, not the primary result report of the randomized comparison. The abstract does not provide evidence of randomization or a comparison between randomized arms, which is essential for eligibility as a primary RCT result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial. PMID 41587107 · Clin Cancer Res · 2026-Jun-15 This record is a genomic/biomarker analysis (ctDNA) from a Phase III randomized trial. It is not the original formal report of the trial's efficacy results (primary or key secondary endpoint). Therefore, it does not meet the 'original_result' criterion for inclusion in a Kaplan-Meier digitization cohort focused on trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. PMID 42294841 · N Engl J Med · 2026-Jun-13 Record explicitly describes a phase 3, randomized, human oncology trial with drug interventions and primary PFS endpoint, meeting all eligibility criteria. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 42288752 · BMC Cancer · 2026-Jun-13 The record is a correction/erratum for a trial, not a primary result report. The title suggests a relevant trial, but without the abstract or full text, key eligibility criteria (phase, time-to-event endpoint, drug intervention details) cannot be established from the provided metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| 6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancreatic cancer in Japan (STARDOM, JON-2402P): study protocol for a multicenter randomized controlled trial. PMID 42286634 · Trials · 2026-Jun-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Bawei Aiguning Granules For Lung Cancer Bone Metastases: A Randomized, Double-blind, Placebo-Controlled Trial Protocol With A Representative Case. PMID 42371923 · J Vis Exp · 2026-Jun-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [Shengqing Jiangzhuo acupuncture method for sepsis-associated gastrointestinal dysfunction: a randomized controlled trial]. PMID 42343512 · Zhongguo Zhen Jiu · 2026-Jun-12 Study is not oncology-related (sepsis-associated gastrointestinal dysfunction). Intervention is acupuncture (non-drug). Primary efficacy endpoints are gastrointestinal function scores and inflammatory markers, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial. PMID 42286774 · Perioper Med (Lond) · 2026-Jun-12 The trial is randomized and oncology-related, but it is not a definitive-phase (Phase III/IIIb or II/III) trial of a drug for an oncological efficacy endpoint. The primary endpoint (postoperative depression incidence) is not a time-to-event efficacy endpoint (e.g., OS, PFS) as required for the oncology Kaplan-Meier digitization cohort. The one-year survival rate is a secondary outcome, but it is not the primary/key secondary endpoint for efficacy evaluation in this context. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Target trial emulation of survival outcomes for clinically localized prostate cancer treatments. PMID 42286375 · Discov Oncol · 2026-Jun-12 The record describes a target trial emulation study using observational data, not a randomized controlled trial report. It lacks a drug intervention and does not report on a Phase III or definitive trial. While it is oncology, human, and reports time-to-event outcomes with HRs, it does not meet the core eligibility criteria of being an original result report from a randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials. PMID 42286315 · Prostate Cancer Prostatic Dis · 2026-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes. PMID 42285355 · Transplant Cell Ther · 2026-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the TiaoShenZhiAi Regimen for Patients With Ovarian Cancer Experiencing a Psychoneurological Symptom Cluster: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. PMID 42284089 · JMIR Res Protoc · 2026-Jun-12 This is a clinical trial protocol for an ovarian cancer study with a randomized design and a drug-containing intervention. However, it is not an original formal-result report; it is a protocol without results. Furthermore, the primary efficacy endpoint is the remission rate of a psychoneurological symptom cluster at 3 months, not a primary/key time-to-event efficacy endpoint (e.g., OS, PFS). The secondary endpoint includes 1-year survival, but this is not sufficient as the primary/key endpoint for inclusion. The phase is not explicitly stated in the provided information, but even if inferred, the other critical criteria (original result report, primary time-to-event endpoint) are not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2). PMID 42134324 · Med · 2026-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial. PMID 42413196 · Int J Gynecol Cancer · 2026-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer. PMID 42276804 · BMJ Open · 2026-Jun-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluation of a virtual Ayurvedic whole-systems lifestyle intervention for quality of life in breast cancer survivors: An exploratory randomized controlled trial. PMID 42320450 · Explore (NY) · 2026-Jun-10 The record describes a randomized, exploratory pilot study of a non-drug, whole-systems Ayurvedic lifestyle intervention (ADRP) for quality of life in breast cancer survivors. It is a Phase II (pilot) trial, not Phase III/IIIb or Phase II/III. It lacks a drug intervention and does not report on any time-to-event efficacy endpoints (OS, PFS, DFS, etc.), focusing instead on patient-reported outcomes like quality of life, sleep, and digestive symptoms. Therefore, it does not meet the core eligibility criteria for inclusion in this oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. PMID 42008768 · J Clin Oncol · 2026-Jun-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. PMID 41576297 · J Clin Oncol · 2026-Jun-10 The trial is oncology, human, randomized, Phase III, has a drug intervention, and reports original primary results. However, it is excluded because the primary endpoint is pCR, which does not meet the time-to-event efficacy endpoint criterion (no OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR reported). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial. PMID 42265476 · Cardiovasc Intervent Radiol · 2026-Jun-09 The record describes a randomized trial in oncology (hepatocellular carcinoma) with a primary time-to-event endpoint (TTP) and reports final results. However, the trial phase (e.g., Phase III) is not explicitly stated in the provided abstract or metadata, and the intervention (TAE vs. DEM-TACE) is a procedure-based comparison, not a drug-containing intervention where the drug is the primary component of the experimental arm. Therefore, eligibility criteria for both 'phase3_or_definitive' and 'drug_intervention' are not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. PMID 42264033 · Clin Microbiol Infect · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Robotic versus open pancreatoduodenectomy (SPAIN Trial): protocol for a multicenter randomized controlled trial assessing safety, efficacy and cost-effectiveness. PMID 42262715 · Updates Surg · 2026-Jun-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Low-fat dietary pattern and dementia mortality: a secondary analysis of the Women's Health Initiative dietary modification randomized clinical trial with long-term follow-up. PMID 42262514 · Menopause · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Dexamethasone Versus N-Acetylcysteine in Prevention of Post-Embolization Syndrome in Hepatocellular Carcinoma Patients: A Multicenter Randomized, Double-Blind, Double-Dummy, Non-Inferiority Trial. PMID 42260068 · Asia Pac J Clin Oncol · 2026-Jun-08 The study is a randomized Phase 3 oncology trial with drug intervention, but its primary endpoint is the incidence of post-embolization syndrome (a complication/safety outcome) at 48 hours, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core criterion for inclusion in a Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial. PMID 42252705 · Cancer Sci · 2026-Jun-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of erector spinae plane, paravertebral, and pectoral nerve blocks on postoperative analgesia and Quality of Recovery-15 in patients undergoing mastectomy: a prospective randomized trial. PMID 42251440 · Perioper Med (Lond) · 2026-Jun-06 Study is a randomized trial in an oncology (breast cancer surgery) setting and reports a time-to-event endpoint. However, it is excluded because the intervention consists of regional anesthesia techniques (nerve blocks) and not a systemic or targeted drug therapy for treatment efficacy. The primary endpoint is total morphine consumption (a safety/analgesic endpoint), not a standard efficacy endpoint like OS/PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial. PMID 42251304 · BMC Cancer · 2026-Jun-06 The study is a well-conducted randomized trial with a drug intervention and time-to-event endpoint, but it does not meet the strict eligibility criteria because: 1) The phase of the trial is not explicitly established as Phase III/IIIb or Phase II/III in the provided abstract (though the START trial is a definitive trial, the phase is not stated here), and 2) This specific analysis is a long-term follow-up/secondary analysis of cancer outcomes rather than the primary trial result report. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Availability of Computer-Aided Detection Devices on Adenoma Detection During Colonoscopy: A Cluster Randomized Study. PMID 42250891 · Gastroenterology · 2026-Jun-05 Study is a cluster randomized pragmatic quality improvement study assessing the impact of a computer-aided detection device on adenoma detection rates during colonoscopy. While oncology-related, it lacks a drug intervention, is not a Phase III or Phase II/III trial, and does not report a primary time-to-event efficacy endpoint like OS, PFS, DFS, etc. Adenoma detection rate is an intermediate surrogate endpoint, not a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. PMID 42249801 · Oncotarget · 2026-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of fibrinogen concentrate (BT524) in severe hemorrhage: Phase 3 subcohort analysis of the AdFIrst trial in patients undergoing cytoreductive surgery for pseudomyxoma peritonei. PMID 42247815 · J Clin Anesth · 2026-Jun-05 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |